整合多组学分析揭示三阴性乳腺癌分子异质性
该研究利用METABRIC和TCGA的拷贝数变异、体细胞突变及基因表达数据,将550例三阴性乳腺癌按Lehmann分子亚型分类,发现各亚型临床病理特征、预后及基因组改变显著不同,IM亚型预后较好而LAR亚型预后较差,并揭示了各亚型潜在驱动事件及候选靶点。
要点
- IM亚型预后较好(HR=0.68),LAR亚型预后较差(HR=1.47)。
- BL1亚型基因组最不稳定,TP53突变率达92%。
- LAR亚型PI3KCA突变富集(55%),IM亚型免疫检查点基因高表达。
核心结论
- TNBC分子亚型存在显著基因组异质性,各亚型预后及驱动事件不同,为靶向治疗开发提供候选靶点。
研究设计与样本
- 基于METABRIC和TCGA的拷贝数变异、体细胞突变及基因表达数据,对550例TNBC样本按Lehmann分子亚型分类。
主要发现
- IM亚型预后较好(HR=0.68;CI=0.46-0.99;P=0.043),LAR亚型预后较差(HR=1.47;CI=1.0-2.14;P=0.046)。
- BL1亚型基因组最不稳定,TP53突变率92%,DNA修复基因(BRCA2、MDM2、PTEN、RB1、TP53)拷贝数缺失。
- LAR肿瘤突变负荷较高,PI3KCA(55%)、AKT1(13%)、CDH1(13%)突变显著富集。
- M和MSL亚型血管生成特征评分较高。
- IM亚型免疫特征及检查点基因(PD1、PDL1、CTLA4)高表达。
临床怎么用
- TNBC分子亚型分类有助于预后分层,IM亚型预后较好,LAR亚型预后较差。
- LAR亚型PI3KCA/AKT1突变富集提示PI3K/AKT通路靶向治疗潜力。
- IM亚型免疫检查点高表达提示免疫治疗可能获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Recent efforts of genome-wide gene expression profiling analyses have improved our understanding of the biological complexity and diversity of triple-negative breast cancers (TNBCs) reporting, at least six different molecular subtypes of TNBC namely Basal-like 1 (BL1), basal-like 2 (BL2), immunomodulatory (IM), mesenchymal (M), mesenchymal stem-like (MSL) and luminal androgen receptor (LAR). However, little is known regarding the potential driving molecular events within each subtype, their difference in survival and response to therapy. Further insight into the underlying genomic alterations is therefore needed. PATIENTS AND METHODS: This study was carried out using copy-number aberrations, somatic mutations and gene expression data derived from the Molecular Taxonomy of Breast Cancer International Consortium (METABRIC) and The Cancer Genome Atlas. TNBC samples (n = 550) were classified according to Lehmann's molecular subtypes using the TNBCtype online subtyping tool (http://cbc.mc.vanderbilt.edu/tnbc/). RESULTS: Each subtype showed significant clinic-pathological characteristic differences. Using a multivariate model, IM subtype showed to be associated with a better prognosis (HR = 0.68; CI = 0.46-0.99; P = 0.043) whereas LAR subtype was associated with a worst prognosis (HR = 1.47; CI = 1.0-2.14; P = 0.046). BL1 subtype was found to be most genomically instable subtype with high TP53 mutation (92%) and copy-number deletion in genes involved in DNA repair mechanism (BRCA2, MDM2, PTEN, RB1 and TP53). LAR tumours were associated with higher mutational burden with significantly enriched mutations in PI3KCA (55%), AKT1 (13%) and CDH1 (13%) genes. M and MSL subtypes were associated with higher signature score for angiogenesis. Finally, IM showed high expression levels of immune signatures and check-point inhibitor genes such as PD1, PDL1 and CTLA4. CONCLUSION: Our findings highlight for the first time the substantial genomic heterogeneity that characterize TNBC molecular subtypes, allowing for a better understanding of the disease biology as well as the identification of several candidate targets paving novel approaches for the development of anticancer therapeutics for TNBC.
引用
- Bareche Y, Venet D, Ignatiadis M, et al. Unravelling triple-negative breast cancer molecular heterogeneity using an integrative multiomic analysis. Ann Oncol. 2018. PMID: 29365031. doi:10.1093/annonc/mdy024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。